Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
IgA nephropathy (IgAN) is the most common type of primary glomerulonephritis. While there is a high risk of progression to end-stage kidney disease within their lifetimes, outcomes vary widely. Galactose-deficient IgA1 (Gd-IgA1) has a key role in the pathogenesis of IgAN, and Gd-IgA1 specifically deposit in the glomeruli in patients with IgAN. Although the indication of immunosuppressive therapy should be determined based on histological and clinical severity, immunosuppressive therapy allows some patients to reach complete remission (CR) of urinary abnormalities and maintain renal function. We aimed to elucidate the histological activity accompanied by glomerular IgA and Gd-IgA1 after immunosuppressive treatment by the repeat renal biopsy.
To analyze pathological improvement in cases with CR, repeat biopsy (Re-Bx) was performed. Immune depositions were analyzed with monoclonal galactose-deficient IgA1 antibody (KM55).
We performed Re-Bx in three patients with CR after immunosuppressive therapy. The interval between the first renal biopsy and the Re-Bx was 4, 10, and 12 years, respectively. A 21 years old man with M0E1S0T0C1 score was performed by tonsillectomy and steroid (PSL) pulse therapy. After 4 years, Re-Bx indicated no significant pathological changes without deposition of Gd-IgA1. A 39 years old woman with M1E1S0T0C1 score was treated with PSL. Re-Bx of 12 years interval showed only several global sclerosis without any immune deposition. A 16 years old woman with M1E0S0T0C1 score was also performed PSL pulse therapy. After 10 years, Re-Bx indicated no significant pathological changes without deposition of Gd-IgA1.
This is the first study to evaluate repeat kidney biopsies at diagnosis and after immunosuppressive therapy in patients with IgAN using KM55 staining. In the components of MEST-C, endocapillary hypercellularity and crescents have been shown to correlate with response to immunosuppressive therapy. Although glomerular IgA persisted in 50% cases, glomerular Gd-IgA1 and C3 were cleared. Thus, the residual IgA may represent non-active deposits rather than disease activity.
Our study demonstrates a series of IgAN patients with CR by immunosuppressive treatment in which disease activity assessed by glomerular Gd-IgA1 was suppressed. Not only existing immunosuppressive treatments, but also new targeting treatments also make it possible for further curable cases worldwide.
